Although type 1 diabetes (T1D) is primarily perceived as a T-cell-driven autoimmune disease, islet autoantibodies are the best currently available biomarker for autoimmunity and disease risk. 
INTRODUCTION
Type 1 diabetes (T1D) is caused by an autoimmune process that leads to the destruction of the insulin-producing -cells in the pancreas (1) . Although T1D is thought to be a primarily T-cell-driven disease, a pathogenic role for B cells has been demonstrated by multiple studies in the NOD mouse model (2, 3) . In humans, autoantibodies produced by B cells are the best currently available biomarker for early -cell autoimmunity.
Subjects with multiple islet autoantibodies have an extremely high risk of developing T1D, with a 5-year risk of around 50% and 15-year risk of more than 80% (4) , and this risk is further increased to almost 90% within 2 years in individuals who also develop impaired glucose tolerance (IGT) (5) . The partial preservation of -cell function with anti-CD20 B cell-depleting rituximab therapy (6) , as well as the demonstration of Bcell tolerance defects in developing naive B cells in patients with T1D (7, 8) , further support an important role for B cells in the pathogenesis of human T1D.
Antibody production by B cells is largely dependent on the help provided by CD4+ helper T cells, most particularly by a CD4+ T-cell subset expressing CXCR5, follicular helper T cells (Tfh) (9, 10) . A subset of peripheral blood memory CD4+ T cells in humans also expresses CXCR5 and recent studies suggest that they represent the circulating memory counterpart of Tfh cells (11) . CXCR5+ memory CD4+ T cells in humans comprise a heterogeneous population and subsets of CXCR5+ T cells with variable Tfh functionality ex vivo have been identified. The most consistent finding has been that the expression of PD-1 and ICOS delineate CXCR5+ T cells with a Tfh-like phenotype. More specifically, PD-1+ICOS-CXCR5+ T cells seem to represent quiescent and PD-1+ICOS+ CXCR5+ T cells recently activated memory Tfh cells (12, 13) .
In recent years, alterations in the circulating Tfh compartment have been observed in multiple autoimmune diseases, such as systemic lupus erythematosus (14) , rheumatoid arthritis (15) (16) (17) , multiple sclerosis (18) and myasthenia gravis (19) . Three recent studies have suggested that circulating Tfh cells are also increased in patients with established T1D (20) (21) (22) . However, the important questions of whether changes in the circulating Tfh compartment occur before the manifestation of clinical T1D and whether they associate with changes in the B-cell compartment and the emergence of serum islet autoantibodies, remain unanswered.
In the current study, we used samples from a large follow-up study of children at 
RESEARCH DESIGN AND METHODS

Study subjects
The study cohort comprised 54 children with newly diagnosed T1D (time after clinical diagnosis 0-7 days; mean age 8.3 years +/-SD 3.6, age range 2-17 years), 58 autoantibody-positive at-risk children (AAb+; mean age 8.3 years +/-SD 4.6, age range 2-17 years), 15 autoantibody-positive at-risk children with impaired glucose tolerance (IGT; mean age 10.7 years +/-SD 4.0, age range 2-18 years) and 149 autoantibody-negative healthy children (controls; mean age 8.8 years +/-SD 4.0, age range 2-16 years). Blood samples for the study were collected over a period of 30 months (August 2013 to January 2016). With the exception of children with newly diagnosed T1D, all study subjects, including the autoantibody-negative healthy control children, participated in the Finnish Type 1 Diabetes Prediction and Prevention Project (DIPP) follow-up study and had HLA-types associated with increased risk for T1D (23) . Autoantibody-positivity was analyzed in the subjects at sampling, as previously described (24) . Autoantibody-positive at-risk subjects (AAb+) were defined based on positivity for one or more biochemical autoantibodies (IAA, IA-2A and/or GADA). Subjects positive for GADA only were excluded from the analyses, since these individuals appear not to have an increased risk for the development of T1D (24) . IGT was determined as an elevated (7.8-11.0 mmol/l) plasma glucose level after a standard 2-hour oral glucose tolerance test (5) . The study has been approved by local ethics committees in the participating university hospitals.
All families participating in the study have provided written informed consent.
PBMC sample preparation
PBMCs were isolated from peripheral blood samples by Ficoll gradient centrifugation, resuspended in RPMI 1640 complete medium +5% human AB-serum and shipped overnight at +4°C from the DIPP study centers in Turku and Tampere to the University of Eastern Finland in Kuopio. Blood samples from healthy age-matched control children were in most cases drawn on the same day and processed in parallel with those from children with newly diagnosed T1D and autoantibody-positive children to control for spurious results caused by differential sample preparation. The viability of the PBMCs before flow-cytometric assays was routinely >97%, as assessed by viability staining.
Flow-cytometric analyses
Surface immunostaining was performed on approximately 10 IgM-class antibody concentrations were measured in the culture supernatants by using the Human IgM ELISA Ready-SET-Go kit (Ebioscience).
Statistical analyses
Statistical analyses were performed using Prism software (GraphPad). When comparing differences between multiple groups one-way ANOVA with Dunnett's posttest was used. Paired t-tests were used when analyzing paired samples. Relationships between different results were examined using Pearson's correlation coefficient. P < 0.05 was considered to indicate statistical significance. Moreover, ICOS expression identifies an activated CXCR5+PD-1+ICOS+ Tfh subset in peripheral blood (13) .
RESULTS
Peripheral
Activated circulating Tfh cells are increased in children with newly diagnosed T1D and in at-risk children with impaired glucose tolerance
We analyzed the circulating Tfh compartment in a total of 54 children with newly diagnosed T1D (within one week of diagnosis), 58 at-risk children positive for islet autoantibodies (AAb+) and 15 AAb-positive children with impaired glucose tolerance (IGT), as well as in 149 age-and HLA-matched AAb-negative healthy control children.
No differences in the frequency of CD4+CXCR5+ T cells within the total CD4+ or memory CD4+ T-cell compartment were observed ( Fig. 2A) , even when the results were stratified by age ( Supplementary Fig. 3 ). Moreover, the frequency of CXCR5+PD-1+ICOS-Tfh cells was comparable between the groups ( Fig. 2B and Supplementary Fig. 3 ). However, the frequency of CD4+CXCR5+PD-1+ICOS+
activated Tfh cells was markedly increased in children with newly diagnosed T1D and in at-risk children with IGT ( Fig. 2C ). We noted that the frequency of CXCR5+PD1+ICOS+ cells within the memory CD4+ T-cell compartment strongly decreased with age ( Supplementary Fig. 3 ). However, a strict pairwise comparison to samples from age-matched healthy children processed and analyzed on the same day confirmed the increase in CXCR5+PD1+ICOS+ Tfh cells in both children with T1D or IGT ( Supplementary Fig. 4) . Importantly, the increase in PD1+ICOS+ cells appeared to be specific for the CXCR5+ compartment as the frequency of CXCR5-PD1+ICOS+ memory CD4+ T cells did not differ between the study groups ( Supplementary Fig. 5 ).
Thus, our results demonstrate that the frequency of CXCR5+PD-1+ICOS+ activated circulating Tfh cells is specifically increased in both children with newly diagnosed T1D as well as in at-risk children with IGT. We also analyzed peripheral blood Tfh frequencies in a separate cohort of adults with long-standing T1D but could not detect differences in the frequency of activated CXCR5+PD-1+ICOS+ Tfh cells in these patients ( Supplementary Fig. 6 ).
Longitudinal analysis reveals that activated circulating Tfh cells are increased near the presentation of clinical disease
Six autoantibody-positive at-risk children that we had analyzed at one or more time points progressed to clinical T1D later during our sample collection period. When we analyzed the data of these subjects longitudinally, we noted that in four of these six children the frequency of CXCR5+PD1+ICOS+ activated circulating Tfh cells increased at the clinical manifestation of the disease (Fig. 3A) . In contrast, in five autoantibody-positive children analyzed repeatedly that did not progress to T1D during our study the frequency of CXCR5+PD1+ICOS+ activated circulating Tfh cells remained stable ( and CXCR3 can be used to classify CD4+CXCR5+ Tfh cells into Tfh1 (CCR6-CXCR3+), Tfh2 (CCR6-CXCR3-) and Tfh17 (CCR6+CXCR3-) subsets (25) . Using this approach ( Supplementary Fig. 1 ) we detected a slight increase of Tfh1-type CXCR5+ T cells in children with newly diagnosed T1D but not in AAb+ at-risk children without or with IGT (Fig. 5A ). No differences in the frequencies of Tfh17-or Tfh2-type CXCR5+ T cells were observed ( Fig. 5B and C) . Interestingly the increase in CXCR3+CCR6-T cells appears not to be restricted to the CXCR5+ compartment since a similar phenomenon was also observed in CXCR5-memory T cells ( Supplementary Fig. 5 ), suggesting a more global shift towards Th1-differentiation in children with newly diagnosed T1D.
The combinations of the CCR7 and PD-1 markers (12) and CXCR3+ and PD-1 markers (13) have also recently been suggested to identify the most Tfh-like population within CD4+CXCR5+ T cells. When we looked at the expression of these markers, we did not observe any differences in the frequency of either CCR7-PD-1+ or CXCR3-PD-1+ Tfh cells between the study groups ( Fig. 5D and E) . Taken together, additional phenotyping of the peripheral blood CD4+CXCR5+ compartment did not reveal major alterations in children with T1D-associated autoimmunity.
Production of IL-21 by CD4+CXCR5+ memory T cells from children with newly diagnosed T1D, autoantibody-positive at-risk children and healthy controls
Since CD4+CXCR5+PD-1+ICOS + activated Tfh cells produce higher amounts of IL-21 ( Fig. 1 ) and the frequency of this subset is increased in children with newly diagnosed T1D (Fig. 2) , we wanted to also analyze the production of IL-21 by T cells Fig. 7 ), allowing us to use CXCR5 to distinguish between CXCR5+ and CXCR5-CD4+ T cells directly ex vivo. In line with our results with sorted T-cell subsets (Fig. 1) , we observed that IL-21 production was consistently higher within the CD4+CD45RA-CXCR5+ Tfh subset than within the CD4+CD45RA-CXCR5-memory T-cell subset ( Fig. 6A; 16 .8+/-0.6 % vs. 12.5+/-0.3%, P < 0.0001, paired t-test, n=103). Similarly, the frequency of IL-21+ cells correlated well with the frequencies of PD1+ICOS-and PD1+ICOS+ cells within CXCR5+ T cells in the same sample and displayed a clear inverse correlation with age ( Fig. 6B and Supplementary Fig. 7 ). No differences in the frequency of IL-21-producing T cells within total memory CD4+ T cells or CXCR5-memory T cells could be observed between the study groups ( Fig. 6C and D) . There was a tendency for a higher frequency of IL-21-producing T cells within CXCR5+ CD4+ T cells in children with T1D but this did not reach statistical significance ( Fig. 6E ; P = 0.08, Dunnett's post-test, and Supplementary Fig. 7 ). We also analyzed the production of IL-21 within the CXCR5+CXCR3+ (Tfh1) and CXCR5+CXCR3-(Tfh2/17) subsets. In general, the frequency of IL-21-producing T cells within the CXCR5+CXCR3+ fraction was slightly higher than in the CXCR5+CXCR3-fraction (17.9+/-0.6% vs. 16.4+/-0.6%, P < 0.0001, paired t-test, n=103) but no differences between the study groups could be observed ( Supplementary Fig. 7 ).
No changes in the B-cell compartment are observed in children with newly diagnosed T1D or in autoantibody-positive at-risk children
Since Tfh cells are major activators of B-cell responses in germinal centers, we also analyzed the composition of the peripheral blood B-cell compartment in our study cohort ( Fig. 7 and Supplementary Fig. 8 ). Specifically, the frequencies of naive B cells CD21low anergic B cells (CD19+CD27-CD21-CD10-CD38-), two subsets that have been previously associated with autoimmunity (26, 27) . Importantly, no differences were observed in the frequencies of these B-cell subsets in children with newly diagnosed T1D or in autoantibody-positive at-risk children compared to healthy controls, even when stratified by age ( Fig. 7 and Supplementary Fig. 9 ). Of note, a positive correlation was detected between the frequency of CXCR5+PD-1+ICOS+ activated circulating Tfh cells and the frequency of plasmablasts (Supplementary Fig.   10 ). In conclusion, no apparent alterations in major peripheral blood B-cell subsets were observed in children with T1D-associated autoimmunity. Our current results are supported by the findings of three recent studies that similarly demonstrate an increase in circulating Tfh cells in patients with established T1D (20) (21) (22) . Although different gating strategies to define Tfh cells as well as patient cohorts differing in age distribution and duration of the disease were used in these studies, two of these studies clearly identified an increase in ICOS+ Tfh cells, as also described here (20, 21) . The increase of ICOS+ activated circulating Tfh cells has also been consistently observed in other autoimmune diseases, such as systemic lupus erythematosus (14) , rheumatoid arthritis (15) (16) (17) , multiple sclerosis (18) and myasthenia gravis (19) . Moreover, in most of these studies this increase has been shown to correlate with the activity of the disease. Our data suggest that the same may also be true in T1D as we did not see any alterations in children with β-cell autoimmunity without impairment of glucose tolerance or in a separate adult cohort of patients with long-standing T1D, although the small number of patients analyzed in the latter cohort precludes definitive conclusion ( Fig. 2C and Supplementary Fig. 6 ).
We also looked at other markers that have been described to differentiate circulating Tfh cells. The combination of CCR6 and CXCR3 separates CXCR5+ Tfh cells into Tfh1 (CCR6-CXCR3+), Tfh17 (CCR6+CXCR3-) and Tfh2 (CCR6-CXCR3-) subsets, of which the Tfh2 and Tfh17 subsets have shown to be more efficient than Tfh1 cells in activating naive B cells in vitro (13, 25) and have been shown to be expanded in some autoimmune diseases (25, 28, 29) . Moreover, the PD-1+CCR7-and PD-1+CXCR3-subsets of CXCR5+ T cells have recently been suggested to contain T cells most closely associated with a true Tfh phenotype (12, 13) . In the current study we did not see major alterations in the circulating CXCR5+ Tfh cells based on these markers. We observed a slightly elevated frequency of Tfh1 (CCR6-CXCR3+) cells in children with newly diagnosed T1D. However, a similar phenomenon was also observed in the CXCR5-memory CD4+ T-cell subset, suggesting that this finding is not a specific alteration in the Tfh compartment but rather represents a more generalized deviation towards Th1-immunity in children with newly diagnosed T1D.
One of the most prominent findings in the current study is that both in children with newly diagnosed T1D and at-risk children with IGT the increase in activated circulating IL-21 is a signature cytokine of Tfh cells and there is evidence from mouse models for an important role for both IL-21 and Tfh cells in pathogenesis of autoimmune diabetes (21, 32) . Two recent studies have also demonstrated an increased frequency of IL-21-producing CD4+ T cells in patients with T1D (21, 22) . However, we were not able to replicate these findings here, as we did not observe any difference in the frequency of IL-21-producing memory CD4+ T cells between our study groups and only a tendency for higher production of IL-21 within the CXCR5+ memory T-cell subset in children with newly diagnosed T1D. Differences in ex vivo stimulation strategies and the age range and disease duration of T1D patients, as well as the lack of statistical power to detect subtle alterations could explain the discrepancy between our results and previous studies. However, it is important to note that IL-21 is not exclusively produced by CXCR5+ Tfh cells, as also demonstrated by our results here ( Fig. 1 and Fig. 6 ). Finally, in this study we comprehensively characterized the B-cell compartment in our large study cohort. In agreement with recent results from another group (34), we observed no alterations in the B-cell subsets analyzed in prediabetic children or in children with newly diagnosed T1D. As reported previously (34, 35) , the frequency of transitional naive B cells decreased sharply with age ( Supplementary Fig. 9 ). An earlier study suggested that the frequency of transitional B cells is increased in T1D patients (36) but in agreement with the more recent results by Thompson et al. (34) , we were unable to corroborate that finding in our cohort. Of note, we observed a positive correlation between the frequency of CXCR5+PD-1+ICOS+ activated circulating Tfh cells and CD19+CD27++CD38++ circulating plasmablasts, as previously also reported by others (17, 18, 37) . This finding is consistent with the idea that the activation of Tfh cells is linked with B-cell activation in vivo. Taken together, our data supports the notion that no major alterations in the circulating B-cell compartment can be observed during the development of T1D in humans.
In conclusion, through an analysis of a large cohort of children at different stages of T1D progression we were able to demonstrate an increase in activated circulating Tfh cells close to the clinical manifestation of the disease. This increase appears to be restricted to a subset of patients that display positivity for multiple autoantibodies.
Therefore, our data provide direct evidence for a pathogenetic role for Tfh cells in progression to T1D, and support for Tfh cells and B cells as potential therapeutic targets in T1D, especially in subjects with multiple autoantibody-positivity. 
